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Focal incidental renal lesions are commonly encountered on positron emission
tomography (PET)/computed tomography (CT) imaging. The vast majority of
these lesions are benign. However, the interpretation of renal lesions can be
problematic if the imaging criteria of simple cysts are not met. Limited
literature exists on the characterisation of renal masses with metabolic
imaging. The purpose of this article is to focus on the imaging features of
benign and malignant renal masses with PET/CT. The lesions discussed
include renal cyst, angiomyolipoma, oncocytoma, renal cell carcinoma, renal
metastases and other infiltrating neoplastic processes affecting the kidney.
Both the anatomical and metabolic features which characterise these benign
and malignant entities are described. We emphasise the importance of
viewing the CT component to identify the typical morphological features and
discuss how to best use hybrid imaging for management of renal lesions.
Metabolic imaging has a promising role in the imaging of renal lesions and can
help prevent unnecessary biopsies and ensure optimal management of sus-
picious lesions.
Key words: computed tomography; diagnostic imaging; positron emission
tomography; renal neoplasm; uroradiology.
Introduction
Hybrid imaging with positron emission tomography
(PET)/ computed tomography (CT) is routinely used in
the assessment of malignant disease. The vast majority
of PET/CT scans are performed with fluorine-18 fluoro-
2-deoxy-D-glucose (FDG), an analogue of glucose. There
is significant uptake and excretion of FDG through the
kidneys which results in intense activity in the renal
collecting system and the bladder (Fig. 1). The use of
FDG PET/CT is thus limited in the evaluation of genitouri-
nary lesions. However, the renal parenchyma is a
common site of incidental findings on hybrid imaging.
Limited literature exists on the imaging appearances and
characterisation of renal masses with metabolic imaging.
This pictorial review illustrates both the anatomical and
metabolic features of a wide spectrum of renal masses
on PET/CT and discusses the current role of hybrid
PET/CT in the imaging of renal lesions. All illustrated
solid lesions were histologically confirmed except for a
suspected renal metastasis in the native kidney post-
renal transplant.
Renal lesions on FDG PET/CT
Renal cyst
Renal cysts are the most commonly encountered renal
lesions, and their prevalence increases with increasing
age, male gender, renal dysfunction and hypertension.1
Renal cystic lesions are usually classified using the
Bosniak criteria which is an internationally recognised
classification (Table 1). The typical appearance of a
simple cyst on CT is of a well-defined, thin walled, low
attenuation lesion (0–20 HU). On hybrid imaging with
FDG PET/CT, simple renal cysts are photopenic (Fig. 2).
Simple renal cysts do not need PET/CT for characterisa-
tion and do not require follow up. The challenge is with
complex cysts and FDG PET/CT has a role for the non-
invasive characterisation of indeterminate cysts (Bosniak
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Types IIF and III) (Fig. 3). In a study by Goldberg et al.,
PET correctly classified indeterminate cysts as benign in
7 of the 8 patients confirmed by surgery or needle
aspiration, and a negative PET scan in conjunction with a
negative cyst aspiration offers confirmatory evidence of
benignity.2 PET/CT can also help in precise anatomic
localisation and percutaneous drainage of an infected
cyst in autosomal dominant polycystic kidney disease
because these are difficult to localise with conventional
imaging.3
Fig. 1. Normal fluorine-18 fluoro-2-deoxy-D-
glucose (FDG) excretion. Coronal attenuated
corrected positron emission tomography
(PET) image (left) and fused PET/CT image
(right) demonstrate normal FDG excretion in
bilateral renal collecting systems (arrow
heads) and bladder (arrows).
Table 1. Bosniak classification of renal cystic disease
Bosniak category Imaging features Role of PET/CT
Category I Simple benign cysts showing homogeneity, water content and a sharp interface with
adjacent renal parenchyma, with no wall thickening, calcification or enhancement
No role in characterisation
Photopenic lesions
Category II Cystic lesions with one or two thin (1 mm thick) septations or thin, fine calcification in
their walls or septa (wall thickening >1 mm advances the lesion into surgical category
III) and hyperdense benign cysts with all the features of category I cysts except for
homogeneously high attenuation
No role in characterisation
Potential role in precise localisation and
drainage of infected cysts
Category II F Minimally complicated cysts that need follow-up. This is a group not well defined by
Bosniak but consists of lesions that do not neatly fall into category II. These lesions
have some suspicious features that deserve follow-up up to detect any change in
character.
Potential role in non-invasive characterisation
Potential role in precise localisation and
drainage of infected cysts
Category III True indeterminate cystic masses that need surgical evaluation, although many prove to
be benign. They may show uniform wall thickening, nodularity, thick or irregular
peripheral calcification, or a multilocular nature with multiple enhancing septa.
Hyperdense lesions that do not fulfil category II criteria are included in this group.
Useful for non-invasive characterisation
Negative PET in conjunction with negative cyst
aspiration offers confirmatory evidence of
benignity
Category IV Lesions with a non-uniform or enhancing thick wall, enhancing or large nodules in the
wall, or clearly solid components in the cystic lesion.
Enhancement was considered present when lesion components increased by at least
10 HU.
Lesion would be best characterised with
contrast enhanced CT/MR and biopsy
confirmation.
Role in restaging and metastatic disease
PET, positron emission tomography.
R Kochhar et al.
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Renal angiomyolipoma
Angiomyolipoma (AML) is the most common benign
tumour of the kidney. It is usually asymptomatic,
although life-threatening haemorrhage can occur. Most
lesions are identified as an incidental finding or following
imaging studies undertaken to investigate haematuria.
In approximately 10% of patients, AML develops as part
of the tuberous sclerosis complex; there is also an asso-
ciation with sporadic lymphangioleiomyomatosis.4 These
lesions characteristically contain variable amounts of
abnormal blood vessels, adipose tissue and smooth
muscle elements. In about 5% of the lesions, a predomi-
nantly solid neoplasm composed of smooth muscle is
seen. The vast majority of AML can be accurately diag-
nosed on unenhanced CT as the lesions contain macro-
scopic fat. Infrequently, a large renal cell carcinoma
(RCC) may contain a small amount of adipose tissue,
making it difficult to differentiate from an AML. AML
rarely contains calcification; therefore, if a lesion has
calcium and fat, RCC must be considered as the likely
diagnosis.5
There is limited literature on the role of FDG PET/CT in
the diagnosis of AML. Of the published data, description
has been variable with one author documenting AML as
metabolically active on FDG PET and falsely positive for
RCC.6 Another group assessing a focal liver mass found
that AML did not have increased FDG uptake but had
increased 11C acetate uptake, which they attributed to
the smooth muscle uptake in that lesion.7 The AML lesion
we encountered did not demonstrate an increased FDG
uptake (Fig. 4) and as such, PET/CT has limited role
characterisation because of the variable uptake. In the
majority of patients, the CT appearances would be the
major criteria in assessing renal AML. However, in
patients where AML develops as a part of the tuberous
sclerosis complex, FDG PET is helpful and can clearly
demonstrate and localise tubers in the brain as
hypometabolic regions compared with the FDG uptake in
the normal brain.8
Renal oncocytoma
Renal oncocytoma are predominantly solid renal
tumours, thought to be benign. They account for 2–3%
of renal tumours, are usually asymptomatic and can be
an incidental finding.9 On unenhanced CT, they usually
appear isodense or hypodense to renal parenchyma. The
mass shows homogenous enhancement which is gener-
ally lower than the surrounding renal parenchyma. If a
central stellate scar is present, it is hypodense on both
pre- and post-contrast images.
Fig. 2. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT appearances of simple renal cyst. Unenhanced CT component (left)
demonstrates well-defined right renal cysts with fluid attenuation (arrow). FDG PET image (centre) and fused PET/CT image (right) demonstrate corresponding
central area of photopenia (arrows), consistent with simple renal cysts. Note also a small simple cyst in the left kidney.
Fig. 3. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT of a complex renal cyst. Unenhanced CT component (left) demonstrates
a complex Bosniak category II/III cyst in the right kidney with a thick calcific wall (arrow). FDG PET image (centre) and fused PET/CT image (right) demonstrate no FDG
uptake in the lesion (arrows). Follow-up was recommended but biopsy/aspiration was not performed.
PET/CT in imaging of renal lesions
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Both oncocytoma and RCC are treated surgically. In
fact, recent articles have reported cases of local recur-
rence and even metastases following resection of onco-
cytoma.10 These observations suggest that oncocytoma
could represent the benign form of malignant chro-
mophobe cell tumours such as RCC.9
As with AML, the published reports on the FDG appear-
ances of oncocytoma are also limited. A recent case
report described an oncocytoma that had significant
uptake of FDG;11 however, oncocytoma may not have
any appreciable uptake of FDG (Fig. 5), limiting the
usefulness of FDG PET/CT in characterisation. The diag-
nostic conundrum that usually arises is the differentia-
tion between oncocytoma and RCC, and metabolic
imaging may not be helpful in differentiating these
lesions.12
Renal cell carcinoma
Worldwide renal cancer accounts for nearly 2% of all
cancers and increases in kidney cancer incidence have
been reported in many different countries around the
world.13 The current classification of RCC describes four
major types, namely: clear cell, chromophil (papillary),
chromophobe and collecting duct type, with the clear cell
RCC being by far the most common type.14 Pre-operative
staging is accurately performed with contrast enhanced
CT. RCC can appear hypodense, isodense or hyperdense
on pre-contrast studies. It usually enhances significantly
post-contrast and can be heterogeneous because of
tumour necrosis.
Only a limited number of studies have investigated the
utility of PET in the assessment of renal masses and
Fig. 4. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT appearances of renal angiomyolipoma (AML). Contrast-enhanced CT
image (left) and fused PET/CT image (right) demonstrate a heterogeneous attenuation lesion with fat attenuation in the lower pole of the right kidney on CT (arrow)
with minimal uptake of FDG on fused PET/CT image (arrow). The lesion has typical CT characteristics of renal AML which are known to have a variable FDG uptake,
confirmed on histopathology.
Fig. 5. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT appearances of a renal oncocytoma. Unenhanced CT image (left)
demonstrates a hypodense soft tissue lesion with tiny specks of calcification (arrow) in the mid pole of the left kidney. Corresponding PET image (right) demonstrates
only minimal heterogeneous uptake of FDG in the lesion. The lesion was a histologically confirmed renal oncocytoma.
R Kochhar et al.
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primary staging of RCC. Bachor et al. studied 29 patients
with solid renal masses and found that PET was true
positive in 20 of 26 patients (77%) with confirmed RCC.6
In one of the larger series on clinical use of PET in
detection of RCC, FDG PET exhibited a sensitivity of 60%
and specificity of 100% for primary RCC, which was
unfavourable to abdominal CT (92% sensitivity and
100% specificity).15 The authors concluded that the role
of FDG PET in the detection of RCC is limited by low
sensitivity. This has been supported by another study
where FDG PET performed for both characterisation and
staging of suspicious renal masses, in a subgroup of 35
patients, showed high false negative rates, leading to a
sensitivity, specificity and accuracy of 47, 80 and 51%,
respectively16.
This is partly because of the excretion of FDG via the
urinary tract as well as the significant variability in
the uptake of FDG by RCC.6,17,18 Various authors have
postulated causes for this inconsistency, including the
variable expression of GLUT- 1 and the lack of avail-
ability of FDG in large tumours as a result of central
necrosis. However, PET-positive tumours have higher
tumour grade and increased GLUT-1.17 In our experi-
ence, FDG uptake in RCC can range from uptake
similar to the background activity to intensely FDG avid
lesions (Figs 6–8). Overall, FDG PET has not greatly
improved the detection and management of primary
renal cancer because the sensitivity and specificity




Fig. 6. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT appearances of a renal cell (RCC) carcinoma with high-grade uptake. (a)
Unenhanced CT component (left) demonstrates a barely perceivable isodense right renal lesion (arrow). The PET image (right) demonstrates focal increased FDG
uptake (arrow) which can be easily mistaken to represent normal uptake in the collecting system (arrow head). (b) Fused PET/CT image (left) clearly localises the
uptake to the renal cortex (arrow) and the adjacent focus of uptake lies within the collecting system (arrow head). Contrast-enhanced CT image (right) confirms the
presence of a small renal tumour in the right kidney (arrow) which showed high-grade FDG uptake and normal appearances for the collecting system (arrow head).
RCC was histopatholically confirmed post-partial right nephrectomy.
PET/CT in imaging of renal lesions
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A meta-analysis of performance of FDG PET in RCC
concluded that PET has a limited role in detection of the
primary disease; however, it can be useful in restaging
and detection of metastatic disease.20 In particular,
PET/CT is useful for lymph node metastases which can
often be falsely negative using the CT size criteria.16,18
FDG PET/CT has been shown to be as good as conven-
tional methods, with 85.7% accuracy in detecting recur-
rence or metastases.21 In addition, it is possible to
examine all organ systems in one procedure with no
need for contrast agents, which can be detrimental to
renal function.
There has been a recent impetus to ascertain tumour
histology before definitive surgery in primary RCC. FDG
PET cannot differentiate between clear cell and papillary
renal cancers. However, Divgi and colleagues have
shown that PET imaging of renal masses, using the
124I-labelled chimeric antibody G250 (124I-G250), is
able to identify correctly clear-cell tumours of the kidney
in most of the patients studied (sensitivity 94%, speci-
ficity 100%).22 This study shows for the first time that
molecular imaging with PET has a role in renal cancer.19
Renal lymphoma and leukaemia
Because the kidneys do not contain lymphoid tissue,
primary renal lymphoma is a rare disease, representing
only 0.1–0.7% of extranodal lymphoma.23 Renal involve-
ment is, however, commonly encountered in patients
with disseminated non-Hodgkin’s lymphoma and is
detected in 3–8% of all patients undergoing routine CT
imaging.24 There are a number of typical radiological
patterns of renal lymphoma, namely: multiple renal
masses, solitary masses, renal invasion from contiguous
retroperitoneal disease, perirenal disease and diffuse
renal infiltration. The commonest appearance on
Fig. 7. Fluorine-18 fluoro-2-deoxy-D-glucose
(FDG) positron emission tomography (PET)/CT
appearances of a renal cell carcinoma (RCC)
with intermediate grade uptake. Unen-
hanced CT image (left) demonstrates an exo-
phytic lesion seen in the lower pole of the
right kidney (arrow). PET image (centre) and
fused PET/CT image (right) demonstrate low
grade uptake in the lesion (arrows) similar to
background renal uptake. This was a histo-
logically confirmed RCC showing only low to
intermediate grade FDG uptake.
Fig. 8. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT appearances of a renal cell carcinoma (RCC) with very low-grade uptake.
Unenhanced CT (left) shows a solid exophytic mass in the mid pole of the right kidney. FDG PET image (centre) and fused PET/CT image (left) demonstrate that the
mass shows minimal FDG uptake, less than the background renal uptake. The lesion was a histologically confirmed RCC with very low grade uptake.
R Kochhar et al.
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contrast-enhanced CT is of multiple bilateral low attenu-
ation renal masses, typically 1–3 cm in size.
There is a paucity of literature describing the appear-
ances of renal involvement in lymphoma on FDG PET/CT.
The discrepancy between the appearances of a distorted
renal parenchymal outline with foci of increased uptake as
opposed to the normal collecting system uptake of FDG
PET should alert the reporting physician. A careful review
of the CT and fused images helps to accurately locate the
site of activity within the renal parenchyma (Fig. 9).
Contiguous retroperitoneal and perirenal pathology
are also seen. Large retroperitoneal masses can invade
and displace the renal hilar structures. These masses do
not typically resolve following therapy; hence, the role of
metabolic imaging in detecting disease recurrence is of
paramount importance. The perirenal pattern could
either be because of disease arising in perinephric lymph
nodes, direct retroperitoneal extension or extension from
the renal parenchyma. These lesions appear as low
attenuation areas on contrast CT, and can be difficult to
detect without intravenous contrast. FDG PET is a useful
tool to detect metabolically active disease surrounding
the perirenal space (Fig. 10). The infiltrative form pre-
sents as bilateral renal enlargement. On FDG PET, it is
difficult to interpret this pattern because of the intense
activity in the renal collecting system.
There is minimal description to date of the imaging
features of leukaemic involvement of the renal paren-
chyma.25 As with lymphoma, primary renal leukaemia is
rare. There are two common presentations of renal leu-
kaemia; a diffuse infiltrative type usually presenting with
renal failure and nephromegaly, and the other form
presenting as focal renal masses (Fig. 11). As renal
impairment often develops secondary to the disease
process, treatment or glomerulonephritis, FDG PET
offers a valuable non-nephorotoxic imaging modality.
Renal metastases
Renal metastases are rare and often clinically silent.
They are small, multicentric and bilateral,26 and can be
easily missed on conventional CT imaging. Among the
Fig. 9. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT appearances of renal lymphoma. Unenhanced CT image (left) demon-
strates an isodense lesion in the left kidney (arrow) and fluid attenuation cystic lesion in the right kidney (short arrow). PET image (centre) and fused PET/CT image
(right) demonstrate markedly increased uptake of FDG in the lesion in the left kidney, in keeping with a metabolically active histologically confirmed lymphomatous
lesion (arrows). The cystic lesion in the right kidney is photopenic (short arrow), typical for a simple cyst.
Fig. 10. Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT appearances of renal lymphoma. Unenhanced CT image (left) demon-
strates bilateral perirenal plaque lesions inseparable from the adjacent renal parenchyma (arrows). PET image (centre) and fused PET/CT image (right) clearly
demonstrate increased FDG uptake in these lesions (arrows). Perirenal masses are one of the more typical patterns of renal lymphoma which can be easily identified
on metabolic imaging, as an intensely FDG avid lesion.
PET/CT in imaging of renal lesions
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Fig. 11. Fluorine-18 fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography
(PET)/CT appearances of renal leukaemia.
Unenhanced CT image (left) reveals no con-
vincing abnormality. PET image (centre)
shows multiple focal areas of intense uptake
of FDG, often confused with uptake in the col-
lecting system. Fused image, however,
clearly localises these focal areas to the renal
cortex with the largest focal lesion seen in the
lower pole of the left kidney (arrows), histo-
logically confirmed renal leukaemic deposit.
Multifocal renal involvement is one of the two
commonest patterns of renal leukaemic
involvement.
Fig. 12. Fluorine-18 fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography
(PET)/CT appearances of renal metastases. (a)
FDG PET/CT image with coronal CT, attenua-
tion corrected and fused images, performed
for suspected solitary pulmonary metastases
in a patient with malignant melanoma con-
firms significant metabolic uptake in a right
lung nodule (arrow heads). High-grade
uptake is also seen in a focal lesion in the mid
pole of the left kidney (arrows) with no con-
vincing abnormality on the unenhanced CT.
(b) Axial contrast-enhanced CT done a month
later showed rapid increase in size (arrow)
and a renal vein thrombus (arrowhead).
Post-operative histology confirmed renal
metastases from malignant melanoma.
(a)
(b)
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primary tumours that are the most common sources of
renal metastases lymphoma, lung cancer and colon
cancer show particularly intense FDG activities.
Metastases to the kidney from these types of primary
malignancies can be detected clearly on FDG PET as
hotspots of increased uptake (Figs 12,13).27
Discussion
The advent of hybrid imaging, especially PET/CT, has
revolutionised the imaging of oncological diseases. Cur-
rently, the role for PET/CT in the work-up of renal lesions
is limited. However, with the increasing utilisation of FDG
PET/CT in cancer, renal lesions are frequently being
detected as incidental findings. There is a paucity of
literature describing the metabolic appearances of
various renal pathologies which has been partly
addressed by this review.
Focal-excreted FDG in the renal pelvicalyceal system
can often be misinterpreted as potential renal lesions on
the PET component, which can be reduced by hydration
and use of diuretics. Respiratory misregistration is
another factor that needs to be taken into account to
avoid misinterpretation. On the other hand, there is a
tendency to underestimate disease by mistaking true
lesions for normal FDG excretion. Scrutiny of the CT
component and fused PET/CT images is needed to mini-
mise both false positive and false negative findings, as
illustrated in Figure 6. The importance of viewing the CT
component to identify the known morphological features
cannot be over-emphasised as the CT component has a
significant contribution to lesion characterisation. The CT
component of fused PET/CT is often an unenhanced CT;
however, PET can now be performed with dedicated
contrast-enhanced renal CT as a single PET/CT exami-
nation which is an exciting prospect to offer complete
Fig. 13. Fluorine-18 fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography
(PET)/CT appearances of a potential renal
metastasis in a native kidney post-renal trans-
plant. (a) Maximum Intensity Projection (MIP)
image (left) demonstrates an FDG avid focus
in the right lung (arrow head), histologically
confirmed small cell cancer and focus of high-
grade uptake in the left renal area (thin
arrow). Unenhanced CT image (top right)
demonstrates bilateral atrophic native
kidneys with a barely perceptible lesion in the
left kidney (arrow). A focus of intense FDG
uptake is seen in the left kidney on the fused
PET/CT (arrow in bottom left image). Note
uptake in a transplant kidney in the left iliac
fossa (short arrow) on the MIP image. (b)
Contrast-enhanced CT confirms an enhanc-
ing lesion in the left kidney (arrow), most
likely in keeping with renal metastasis in the
native left kidney from a primary lung cancer.
(a)
(b)
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morphological and metabolic assessment in a single
examination.
For accurate characterisation of renal lesions, dedi-
cated ultrasound, contrast-enhanced renal CT and MRI
are very useful. Ultrasound and contrast-enhanced CT
remain the modalities of choice in renal imaging. The
role of MRI in renal imaging is still mainly in differenti-
ating benign lesions versus malignant lesions in patients
who cannot undergo CT scanning with intravenous iodi-
nated contrast media, or in cases with non-diagnostic CT
results as a problem-solving modality. MRI can have
additional diagnostic value in the evaluation of lesions
with minimal amounts of fat or with intracellular fat.
Data suggest that MRI has a higher sensitivity in evalu-
ating complicated cysts; however, the clinical implica-
tions still have to be studied.28
The economic impact of the use of PET/CT in charac-
terisation of renal lesions needs consideration. This can
be assessed through a cost-effectiveness analysis of
different diagnostic strategies performed, for example,
in a recent study in which PET/CT was introduced in the
clinical management of patients with suspected recur-
rence of ovarian cancer.29 In our experience, PET/CT
used in selected high-risk patients, for example in
patients with recurrent RCC, can prove to be cost effec-
tive by redirecting the clinical management of patients
towards more appropriate therapeutic choices.
The imaging features and potential role of PET/CT in
some of the common renal lesions have been sum-
marised in Table 2. FDG PET/CT can help in the charac-
terisation of indeterminate cysts, is useful for post-
operative surveillance of advanced RCC and can clearly
detect FDG avid intraparenchymal renal metastases.
PET/CT used with other novel metabolites also has a role
in the preoperative characterisation of primary RCC and
the variability of FDG avidity may also find use in tumour
metabolic phenotype determination. The take home
messages have been summarised in Table 3.
Conclusion
Many different renal lesions can be detected clearly as
hotspots of elevated uptake on FDG PET/CT. However,
excreted FDG in the urinary tract mimics disease and can
interfere with image interpretation. The illustrated cases
have demonstrated that by combining careful evaluation
of the renal cortex by FDG PET to detect hot spots and
correlating it with the anatomical information on the CT
component, this modality has the potential to have a role
in the imaging of renal lesions. With the increasing use of
PET/CT, a knowledge of both morphological and meta-
bolic characteristics of renal lesions on hybrid imaging
is essential to help prevent unnecessary biopsies and
ensures optimal management of suspicious lesions.
Table 2. FDG PET/CT imaging of renal pathologies
Renal pathology Findings on CT Findings on FDG PET Role of FDG PET/CT
Renal angiomyolipoma
(AML)
Detection of macroscopic fat on CT is the
key diagnostic feature.
Variable FDG uptake
No role in characterisation
Useful in patients with AML associated
with tuberous sclerosis complex
Renal oncocytoma Iso or Hypodense to renal parenchyma.
Homogenous enhancement with central
stellate scar
Variable FDG uptake
No role in characterisation
Limited role: in particular not useful in
differentiation from renal cell
carcinoma (RCC)
RCC Hypo, Iso or Hyperdense on unenhanced CT
Significant post-contrast enhancement, at
times heterogeneous as a result of
tumour necrosis
Variable FDG uptake correlated with tumour
grade, GLUT-1 receptors and degree of
tumour necrosis.
Limited role in diagnosis and staging of
primary disease
Useful role in restaging and detection of
metastases
Renal lymphoma Radiological patterns: multiple and solitary
masses, contiguous retroperitoneal
disease, perirenal disease and diffuse
renal infiltration
Foci of increased uptake with distorted renal
parenchymal outline (as opposed to
normal collecting system uptake)
Useful to detect metabolically active
residual and recurrent disease
Renal leukaemia Diffuse infiltrative type seen as
nephromegaly or focal masses
Limited literature. Multifocal type seen as
FDG avid renal lesions
Valuable non-nephorotoxic imaging
modality.
Renal metastases Small, multicentric, bilateral hypodense
lesions. Easily missed on CT
Multiple focal FDG avid intrarenal lesions Lesions clearly detected with FDG
PET/CT
FDG, fluorine-18 fluoro-2-deoxy-D-glucose; PET, positron emission tomography.
Table 3. Take home messages
1 Excreted fluorine-18 fluoro-2-deoxy-D-glucose (FDG) in the urinary tract
can mimic disease
2 PET/CT has a potential role in characterisation of indeterminate renal
cysts.
3 Low sensitivity of FDG PET/CT limits its role in detection of primary renal
cell carcinoma (RCC) but other novel metabolites can help in the
preoperative characterisation of tumour type.
4 PET/CT has a useful role in recurrent, metastatic RCC and renal
metastases.
5 PET/CT has a limited role in the characterisation of renal masses because
of variability of uptake, but can be used as a problem-solving modality.
6 Careful scrutiny of the CT component and use of contrast-enhanced CT as
a part of the PET/CT is advised.
R Kochhar et al.
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